Bilfinger’s stock has been hammered from all sides in 2026, shedding more than a third of its value since February to trade at €79.30 — a drop of roughly 2.3% on the latest session alone. Yet amid the gloom, Morgan Stanley has quietly increased its exposure, now holding 6.41% of voting rights as of 25 May. The stake, which comprises 4.13% directly attributable to roughly 1.55 million shares and another 2.28% through an equity swap and securities lending arrangements, is a pure financial investment rather than a prelude to a takeover. No control event has been triggered, and the move remains a standard regulatory filing under German securities law.
The timing of that accumulation looks contrarian at best. Just days after the reporting threshold was crossed, a labour dispute has erupted on Bilfinger’s offshore assets in the UK North Sea. Around 20 workers represented by the Unite union plan a series of strikes over a retention bonus scheme that was not extended to them. Industrial action began today, 4 June, on the Alba Floating Storage Unit and is scheduled to run through 7 June, followed by four more days of stoppages on the FPF‑1 platform from 9 to 12 June. The underlying contract belongs to Ithaca Energy, and while the affected sites are separate from Bilfinger’s larger Cygnus and St. Fergus SAGE operations, the company’s reputation for operational reliability — its core selling point in the energy services sector — is squarely at risk.
Bilfinger is trying to pivot away from such cyclical exposures. In May, it secured a £15 million maintenance contract for a biopharmaceutical production plant in Scotland, with an initial three‑year term and options to extend. Around 60 staff will transfer from the incumbent provider. That deal fits into a broader strategic push into highly regulated life‑science environments, where longer budget cycles and compliance‑driven demand are expected to reduce earnings volatility. Management has held its 2026 guidance: revenue between €5.4 billion and €5.9 billion, an EBITA margin of 5.8% to 6.2%, and free cash flow of €250 million to €300 million.
Should investors sell immediately? Or is it worth buying Bilfinger?
First‑quarter results offered a mixed foundation. Revenue rose 4% year‑on‑year to €1.312 billion, and the EBITA margin came in at 4.6%. But order intake slipped 5% to €1.208 billion, a blemish that has weighed on investor sentiment ever since. The stock now carries a relative strength index of 27.4, deep in technically oversold territory, and trades 23% below its 200‑day moving average of €103.28 — a stark illustration of how far the market has repriced the group’s prospects.
So far, the market seems to be weighing the strike disruption and the order‑book softness more heavily than either Morgan Stanley’s endorsement or the life‑science contract. The next catalyst for the share price is likely to be whether the bonus dispute is resolved quickly and whether Bilfinger can bundle more high‑visibility deals like the Scottish biopharma win into its pipeline. For now, the biggest investor vote of confidence sits in Morgan Stanley’s 6.41% — but it has yet to convince the broader market to follow suit.
Ad
Bilfinger Stock: Buy or Sell?! New Bilfinger Analysis from June 5 delivers the answer:
The latest Bilfinger figures speak for themselves: Urgent action needed for Bilfinger investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from June 5.
Bilfinger: Buy or sell? Read more here...
